NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer Screening
Not Applicable
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00131950
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1
Completed
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Interventions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00131989
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00132067
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Epidemiology of Gallbladder Sludge and Stones in Pregnancy
Not Applicable
Completed
- Conditions
- Cholelithiasis
- Interventions
- Behavioral: Exercise
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 1196
- Registration Number
- NCT00131131
- Locations
- 🇺🇸
Madigan Army Medical Center, Tacoma, Washington, United States
Biofeedback for Dyssynergic Constipation
Not Applicable
Completed
- Conditions
- Constipation
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2010-01-13
- Target Recruit Count
- 117
- Registration Number
- NCT00127257
- Locations
- 🇺🇸
University of North Carolina Department of Medicine, Chapel Hill, North Carolina, United States
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 2
Completed
- Conditions
- Fallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00126542
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
Phase 2
Terminated
- Conditions
- Anaplastic Thyroid CancerRecurrent Thyroid Cancer
- Interventions
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00126568
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
Phase 2
Completed
- Conditions
- Recurrent Skin CancerSquamous Cell Carcinoma of the Skin
- Interventions
- Radiation: RadiotherapyOther: laboratory biomarker analysisProcedure: Conventional surgery
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT00126555
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung AdenocarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7Malignant Pericardial EffusionMalignant Pleural EffusionLung Adenosquamous CarcinomaMinimally Invasive Lung AdenocarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 188
- Registration Number
- NCT00126581
- Locations
- 🇺🇸
University Medical Center of Southern Nevada, Las Vegas, Nevada, United States
🇺🇸Kaiser Permanente-San Diego Mission, San Diego, California, United States
🇺🇸Veterans Administration-San Diego Medical Center, San Diego, California, United States
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Phase 2
Terminated
- Conditions
- High-grade Salivary Gland Mucoepidermoid CarcinomaRecurrent Salivary Gland CancerSalivary Gland Acinic Cell TumorSalivary Gland AdenocarcinomaSalivary Gland Poorly Differentiated CarcinomaStage IVA Salivary Gland CancerStage IVB Salivary Gland CancerStage IVC Salivary Gland Cancer
- Interventions
- Biological: trastuzumabOther: laboratory biomarker analysis
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00126607
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States